Daiichi Sankyo Co Ltd - Tokyo-based pharmaceutical company - Enhertu gets US Food & Drug Administration approval for two new indications for adult patients with HER2 positive early breast cancer. Enhertu is approved in the adjuvant setting for patients with HER2 positive breast cancer who have residual invasive disease following neoadjuvant trastuzumab and taxane-based treatment. Enhertu is an antibody drug conjugate being jointly developed and commercialised alongside London-based AstraZeneca PLC. The treatment now has approvals for nine indications, with six across early and metastatic HER2 positive breast cancer.
"HER2 positive breast cancer is an aggressive disease, and our goal is to reduce the risk of recurrence as early as possible to achieve the best long-term outcomes. The neoadjuvant setting offers the earliest opportunity to improve outcomes, while the adjuvant setting provides another important chance to prevent recurrence for patients with residual disease after surgery," says Shanu Modi, medical oncologist, Memorial Sloan Kettering Cancer Center and principal investigator for the Destiny-Breast11 trial. "These two new indications in HER2 positive early breast cancer will evolve how we treat patients in these settings and support trastuzumab deruxtecan as a potential new standard of care in early-stage disease."
Current Daiichi Sankyo stock price: JPY2,574.00
12-month change: down 30%
Current AstraZeneca stock price: 13,584.00 pence
12-month change: up 31%
By Elijah Dale, Alliance News senior reporter Asia-Pacific
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.



